Literature DB >> 6104615

Chronic use of triazolam: the effects on the sleep patterns of insomniacs.

V Pegram, P Hyde, P Linton.   

Abstract

The present study was designed to evaluate the effects of triazolam 0.5 mg on the sleep of insomniac patients when given for 3 weeks. The results showed that both acute and chronic triazolam administration are effective in decreasing sleep latency, increasing sleep duration, increasing sleep efficiency and decreasing total wake time without producing major effects on sleep staging. Sleep Stages 1 and 2 were significantly altered by drug treatment but in a positive direction. This change is primarily attributable to the significant decrease in sleep onset. Deep sleep and REM were not significantly changed during triazolam treatment nor was there any evidence of REM rebound after discontinuation of the medication. It was noted that some of the sleep parameters measured shifted toward baseline measures in the first night after triazolam treatment was terminated. However, the total recovery period recorded (7 days) showed the quality and quantity of sleep obtained to be improved over baseline measures. The recovery data compared favourably with those improvements noted during chronic administration of triazolam. It was also found that 3 weeks of triazolam 0.5 mg usage did not result in tolerance to its hypnotic properties. Thus, triazolam maintains its hypnotic effectiveness throughout 3 weeks of administration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104615     DOI: 10.1177/030006058000800308

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

1.  Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold.

Authors:  C L Spinweber; L C Johnson
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 2.  Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

Review 3.  An assessment of short-acting hypnotics.

Authors:  W B Mendelson; B Jain
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

4.  Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?

Authors:  Christiaan H Vinkers; Berend Olivier
Journal:  Adv Pharmacol Sci       Date:  2012-03-29

Review 5.  Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review.

Authors:  Laura Palagini; Carlotta Bianchini
Journal:  Front Neurosci       Date:  2022-07-29       Impact factor: 5.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.